Background/aims: The porphyrias are genetically heterogeneous diseases, and each mutation is exclusive to one or two families. Among the mutations responsible for variegate porphyria in our country, c.1042_1043insT stands out, since it was described only in Argentina and is present in about 40% of genetically diagnosed families. Thus, we hypothesized the possible existence of a common ancestor for the mutation in our population.
Methods: We conducted a study based on microsatellite (short tandem repeats) haplotypes.
Results: We found a common haplotype in all of the patients carrying the common mutation. The age of the mutation was estimated to be about 375 years.
Conclusion: There is a recent founder effect in our population for this particular genetic alteration in variegate porphyria.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000445749 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A 38-year-Old Woman With Flaccid Tetraparesis after Presenting With Abdominal Pain.
Neurohospitalist
September 2024
Hospital Israelita Albert Einstein, São Paulo, Brazil.
Article Synopsis
- - A 38-year-old woman experienced severe abdominal pain and underwent laparoscopic surgery to remove her gallbladder.
- - After the surgery, she suffered from various complications, including increasing abdominal pain, rapid heart rate, muscle weakness, and issues with urination and bowel movements.
- - Testing revealed a high level of porphobilinogen in her urine, highlighting the importance of evaluating different diagnoses when abdominal pain is accompanied by neurological symptoms.
Hepatocellular Carcinoma in Acute Hepatic Porphyria: A Meta-Analysis of Observational Studies.
Dig Dis Sci
November 2024
University of Texas Medical Branch, Galveston, TX, USA.
Article Synopsis
- Hepatocellular carcinoma (HCC) is a potential long-term complication for patients with acute hepatic porphyria (AHP), and this study aims to assess its incidence and identify high-risk groups.
- The meta-analysis included data from 12 studies with 2,735 AHP patients, revealing an overall HCC incidence of 0.3% per year, with higher rates in specific subtypes like acute intermittent porphyria (AIP) and in older females, symptomatic patients, and those with additional liver disease risk factors.
- The findings highlight the need for future research to create effective screening and surveillance strategies for HCC in AHP patients, due to the identified
Therapeutic approach to acute crises of hepatic porphyrias.
Rev Clin Esp (Barc)
December 2024
Unidad de Enfermedades Raras y Autoinmunes Sistémicas, Servicio de Medicina Interna, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Article Synopsis
- - Acute hepatic porphyria is a genetic disorder that affects the production of heme and is primarily caused by issues with specific enzymes, with acute intermittent porphyria being the most common type.
- - Triggered by factors that induce the enzyme ALA synthase 1, this disorder leads to the buildup of toxic heme intermediates, causing severe symptoms such as abdominal pain, muscle weakness, and autonomic dysfunction; women are more prone to these attacks than men.
- - Prompt recognition and treatment are essential, requiring urgent medical interventions like intravenous opioids and glucose, while preventive measures include hormone suppression and possibly liver transplantation.
[An overview of porphyrias].
Dermatologie (Heidelb)
July 2024
Klinik für Dermatologie, Venerologie und Allergologie, Universitätsmedizin Göttingen, Robert Koch Str. 40, 37075, Göttingen, Deutschland.
Article Synopsis
- Porphyrias are genetic metabolic disorders that disrupt enzymes involved in producing porphyrin and heme, leading to toxic byproducts like porphyrins.
- Symptoms vary widely, including skin issues in sunlight and dangerous neurovisceral attacks.
- Diagnosis involves biochemical tests of urine, blood, and stool, and treatment is complex, often needing collaboration among various medical specialists.
Understanding Hepatic Porphyrias: Symptoms, Treatments, and Unmet Needs.
Semin Liver Dis
May 2024
Department of Experimental Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Article Synopsis
- - Hepatic porphyrias are metabolic disorders where excess porphyrin precursors accumulate in the liver, leading to neurological symptoms and skin sensitivity, with some cases resulting in severe acute neurovisceral attacks.
- - This review focuses on types of acute hepatic porphyrias (like acute intermittent porphyria and hereditary coproporphyria) and those with skin symptoms (like porphyria cutanea tarda), addressing prevalence, symptoms, and treatments.
- - It also explores new treatment options, such as gene therapy using adeno-associated vectors and innovative chaperone therapies like lipid nanoparticles and small interfering RNA-based treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!